Progenics Pharmaceuticals (PGNX +2.2%) reports positive clinical data from a completed Phase 1...

Progenics Pharmaceuticals (PGNX +2.2%) reports positive clinical data from a completed Phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen. The tests showed the drug was generally well tolerated in patients at doses up to and including the maximum tolerated dose.